Phase1/2 study of nab-Paclitaxel + trastuzumab therapy in 2nd line treatment for HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab combined with fluoropyrimidine and platinum.
Phase of Trial: Phase I/II
Latest Information Update: 18 Sep 2018
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary) ; Trastuzumab
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Sep 2018 Status changed from recruiting to discontinued.
- 03 Sep 2014 New trial record